|
Post by cjm18 on Jun 4, 2019 9:43:13 GMT -5
No ‘long FUD’ about it. Thread is talking about things that might happen in next 6 mo. Possibilities. MNKD is not predictable - no reason a stock buyback is not a possibility at these low prices. Would be great to see an activist or more come in and make huge buys - something like that could happen too. You do realize there is 100 million in debt and insulin obligations on the books after Deerfield is paid off. There will not be a stock buyback. I stand by my statement that it is just as irresponsible fud to say a buyback is possible. Funny mk said buyback was possible.
|
|
|
Post by cretin11 on Jun 4, 2019 9:49:19 GMT -5
You do realize there is 100 million in debt and insulin obligations on the books after Deerfield is paid off. There will not be a stock buyback. I stand by my statement that it is just as irresponsible fud to say a buyback is possible. Funny mk said buyback was possible. Stock buyback makes absolutely no sense. People call out what they think is “FUD” but to speculate a stock buyback is more egregious in the other direction.
|
|
|
Post by cretin11 on Jun 4, 2019 9:50:50 GMT -5
So mnkd finally received approval in Brazil. What is in store for the next six months as we reach the half way point in the year? (I am only including items that have a reasonable of occurring) The Good: 1. DF payoff (cash or shares? Has mnkd been using the atm to raise the funds?) 2. Second UTHR molecule 3. Second UTHR milestone payment for 2019 4. Mexico/Canada filings 5. Told we would hear more about RLS this year. 6. ADA Posters 7.Results of One Drop Study 8. Publication in major journal(s) as promised 9. Progress report on Peds study 10. Percent exercise of $1.60 warrants 11. Scripts hit 900 by year’s end The Bad: 1. Dilution (How much? And when?) 2. DF milestone payment Clearly the good outweighs the bad imho. It will be a slow grind up but at least mnkd seems headed in the right direction. Very Good list. The $1.60 Warrants expire in December so there's a good chance the stock price will be over $1.60. I'm hoping the Phase 3 Peds Trial will begin in 4Q since Mike said Cohort 3 should move faster than the first 2. I'm assuming your 900 script target is for WEEKLY. I don’t understand why you say there’s a good chance stock will be over $1.60 in Dec because warrants expire? That has never proven true before.
|
|
|
Post by Omega on Jun 4, 2019 10:08:23 GMT -5
So mnkd finally received approval in Brazil. What is in store for the next six months as we reach the half way point in the year? (I am only including items that have a reasonable of occurring) The Good: 1. DF payoff (cash or shares? Has mnkd been using the atm to raise the funds?) 2. Second UTHR molecule 3. Second UTHR milestone payment for 2019 4. Mexico/Canada filings 5. Told we would hear more about RLS this year. 6. ADA Posters 7.Results of One Drop Study 8. Publication in major journal(s) as promised 9. Progress report on Peds study 10. Percent exercise of $1.60 warrants 11. Scripts hit 900 by year’s end The Bad: 1. Dilution (How much? And when?) 2. DF milestone payment Clearly the good outweighs the bad imho. It will be a slow grind up but at least mnkd seems headed in the right direction. #2 I'm excited to find out more about. "2. Second UTHR molecule"
|
|
|
Post by matt on Jun 4, 2019 10:47:37 GMT -5
No ‘long FUD’ about it. Thread is talking about things that might happen in next 6 mo. Possibilities. MNKD is not predictable - no reason a stock buyback is not a possibility at these low prices. Would be great to see an activist or more come in and make huge buys - something like that could happen too. You do realize there is 100 million in debt and insulin obligations on the books after Deerfield is paid off. There will not be a stock buyback. I stand by my statement that it is just as irresponsible fud to say a buyback is possible. There are also legal barriers to doing a stock buyback. MNKD meets the legal definition of bankrupt in the State of Delaware because of the negative shareholder equity on the books. A stock buyback reduces the assets available to pay creditors and since there are not enough liquid assets for the company to meet all of their liabilities, a buyback would be considered a fraudulent conveyance. The consequences of a fraudulent conveyance are complex, but suffice it to say the shareholders who are bought out would have to return the money and there are personal legal ramifications for officers and directors as well.
|
|
|
Post by sportsrancho on Jun 4, 2019 11:06:01 GMT -5
Long fud, shorts fud. Whatever...I listen to it every day!! I’m on a thread of six MNKD Long’s that have more shares combined then you can imagine and they are negative everyday...the pps sucks...so quit whining because you hear skepticism, negativity, or what you think is pumping.
I’m not buying into the share buyback, but I would sure take an activist:-)
|
|
|
Post by prcgorman2 on Jun 4, 2019 13:39:22 GMT -5
I'm negative - about negativity. :-)
|
|
|
Post by sportsrancho on Jun 4, 2019 14:10:34 GMT -5
I’ve learned since I get hit with negativity everyday or when someone keeps arguing with me, to just say, “OK” that ends the whole conversation 😉
|
|
|
Post by hellodolly on Jun 4, 2019 14:29:22 GMT -5
I’ve learned since I get hit with negativity everyday or when someone keeps arguing with me, to just say, “OK” that ends the whole conversation 😉 Some times the best way to do it...just step side. I do that when I feel it's just not worth it. On the flip side, I'm a bull dog if I do feel passionate about something, as do you. Just a different trait, but both have their pros and cons.
|
|
|
Post by sportsrancho on Jun 4, 2019 14:38:59 GMT -5
I’ve learned since I get hit with negativity everyday or when someone keeps arguing with me, to just say, “OK” that ends the whole conversation 😉 Some times the best way to do it...just step side. I do that when I feel it's just not worth it. On the flip side, I'm a bull dog if I do feel passionate about something, as do you. Just a different trait, but both have their pros and cons. Agree, sometimes when I argue about it I just create more of it. Like on StockTwits if you argue with a short all you get are more posts with his opinion which is exactly what you didn’t want.
|
|
|
Post by mnkdfann on Jun 5, 2019 18:29:46 GMT -5
So mnkd finally received approval in Brazil. What is in store for the next six months as we reach the half way point in the year? (I am only including items that have a reasonable of occurring) The Good: 1. DF payoff (cash or shares? Has mnkd been using the atm to raise the funds?) 2. Second UTHR molecule 3. Second UTHR milestone payment for 2019 4. Mexico/Canada filings 5. Told we would hear more about RLS this year. 6. ADA Posters7.Results of One Drop Study 8. Publication in major journal(s) as promised 9. Progress report on Peds study 10. Percent exercise of $1.60 warrants 11. Scripts hit 900 by year’s end The Bad: 1. Dilution (How much? And when?) 2. DF milestone payment Clearly the good outweighs the bad imho. It will be a slow grind up but at least mnkd seems headed in the right direction. The items listed are all significant, but I'm not so sure that so many of them are unambiguously good. For instance, results and progress reports needn't be good (they could be serious downers), and publications may not be in 'major' journals. Regarding the latter point, the publication experience to date suggests that forthcoming articles might appear in second (or third) tier places. (I'm not saying these things are more likely to be bad than good, just that a lot of them could be sort of a wash / neutral.) The rather poor (all things considered) ADA pediatric study poster may have just proven my point.
|
|
|
Post by goyocafe on Jun 5, 2019 19:09:35 GMT -5
The items listed are all significant, but I'm not so sure that so many of them are unambiguously good. For instance, results and progress reports needn't be good (they could be serious downers), and publications may not be in 'major' journals. Regarding the latter point, the publication experience to date suggests that forthcoming articles might appear in second (or third) tier places. (I'm not saying these things are more likely to be bad than good, just that a lot of them could be sort of a wash / neutral.) The rather poor (all things considered) ADA pediatric study poster may have just proven my point. Point taken, but if the current pediatric study is to determine safety and tolerability (and they achieve the endpoints defined in the study) they can certainly introduce a more manageable protocol for phase III and still make a big impact on the pediatric market. It comes down to Mannkind really understanding ALL of the factors in a study and take care in implementing and administering it.
|
|